176 related articles for article (PubMed ID: 36091057)
1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
Front Immunol; 2022; 13():946522. PubMed ID: 36091057
[TBL] [Abstract][Full Text] [Related]
2. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
[TBL] [Abstract][Full Text] [Related]
3. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.
Senent Y; Inogés S; López-Díaz de Cerio A; Blanco A; Campo A; Carmona-Torre F; Sunsundegui P; González-Martín A; Ajona D; Okrój M; Prósper F; Pio R; Yuste JR; Tavira B
Front Immunol; 2021; 12():767376. PubMed ID: 34868021
[TBL] [Abstract][Full Text] [Related]
4. Erythrocytes identify complement activation in patients with COVID-19.
Lam LKM; Reilly JP; Rux AH; Murphy SJ; Kuri-Cervantes L; Weisman AR; Ittner CAG; Pampena MB; Betts MR; Wherry EJ; Song WC; Lambris JD; Meyer NJ; Cines DB; Mangalmurti NS
Am J Physiol Lung Cell Mol Physiol; 2021 Aug; 321(2):L485-L489. PubMed ID: 34231390
[TBL] [Abstract][Full Text] [Related]
5. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
Front Immunol; 2021; 12():707159. PubMed ID: 34966381
[TBL] [Abstract][Full Text] [Related]
6. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
Front Immunol; 2021; 12():714511. PubMed ID: 34290717
[TBL] [Abstract][Full Text] [Related]
7. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
Front Immunol; 2021; 12():765330. PubMed ID: 34777382
[TBL] [Abstract][Full Text] [Related]
8. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
[TBL] [Abstract][Full Text] [Related]
9. Complement activation products in the circulation and urine of primary membranous nephropathy.
Zhang MF; Huang J; Zhang YM; Qu Z; Wang X; Wang F; Meng LQ; Cheng XY; Cui Z; Liu G; Zhao MH
BMC Nephrol; 2019 Aug; 20(1):313. PubMed ID: 31399080
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M
J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462
[TBL] [Abstract][Full Text] [Related]
11. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
[TBL] [Abstract][Full Text] [Related]
12. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial.
Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
[TBL] [Abstract][Full Text] [Related]
13. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Lonati P; Grossi C; Borghi MO; Novembrino C; Boscolo M; Uceda Renteria SC; Valenti L; Lamorte G; Manunta M; Prati D; Pesenti A; Blasi F; Costantino G; Gori A; Bandera A; Tedesco F; Peyvandi F
J Autoimmun; 2021 Jan; 116():102560. PubMed ID: 33139116
[TBL] [Abstract][Full Text] [Related]
14. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
[TBL] [Abstract][Full Text] [Related]
15. The synthesis of a water soluble complement activating polyacrylic acid-IgG polymer.
Schmer G; Henderson RA; Müller W
J Biomater Sci Polym Ed; 1994; 6(1):67-78. PubMed ID: 7947474
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.
Ajona D; Razquin C; Pastor MD; Pajares MJ; Garcia J; Cardenal F; Fleischhacker M; Lozano MD; Zulueta JJ; Schmidt B; Nadal E; Paz-Ares L; Montuenga LM; Pio R
PLoS One; 2015; 10(3):e0119878. PubMed ID: 25799154
[TBL] [Abstract][Full Text] [Related]
17. [Involvement of the complement cascade in severe forms of COVID-19].
Chouaki Benmansour N; Carvelli J; Vivier É
Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
[TBL] [Abstract][Full Text] [Related]
18. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
Banda NK; Levitt B; Wood AK; Takahashi K; Stahl GL; Holers VM; Arend WP
Clin Exp Immunol; 2010 Jan; 159(1):100-8. PubMed ID: 19843088
[TBL] [Abstract][Full Text] [Related]
19. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
[TBL] [Abstract][Full Text] [Related]
20. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
Gyongyossy-Issa MI; McLeod E; Devine DV
J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
